OTCA09 “High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer” Final Project Plan Now Available
[vc_row][vc_column][vc_column_text]This is the final project plan of the assessment on “High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer” and the comments provided by an external expert during scoping. Project Plan_HIFU_final Project Plan external reviewer comments and authors’ answers[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space][/vc_column][/vc_row]
OTJA08 Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin
The final project plan of the assessment on “Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems” and the comments provided by the external experts and the manufacturers are now available. OTJA08_Project_Plan_CGM_and_FGM OTJA08_Compiled_comments_answers_PP_external_experts_manufacturers
Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard cataract surgery
Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard cataract surgery This is the final project plan of the assessment on “Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard cataract surgery” and the comments provided by one manufacturer during a fact check of the draft project plan. Project […]
WP4 OTCA03 on “Screening of fetal trisomies 21, 18 and 13 by non invasive prenatal testing” is now available
This is the assessment of the relative effectiveness of “Screening of fetal trisomies 21, 18 and 13 by non invasive prenatal testing”. The purpose of the assessment is to evaluate the relative effectiveness and safety of noninvasive prenatal testing (NIPT) for the screening of fetal trisomy 21, trisomy 18 and trisomy 13 in comparison to […]
WP4 PTJA03 on “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)” is now available
This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)”. This is a revised version of the report originally posted on January 23, 2018. An error was identified in table 0.1 and table A21, in which […]
